Compare Hims and Hers Health Inc (HIMS) vs HSBC Holdings plc (HSBC) Price & Performance

Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.

The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.

HSBC trades at $103.73, up 1.14% today, with a bullish technical signal from moving averages and support at $102. The stock shows strong fundamentals with a P/E of 14.76, net income margin of 34.54%, and ROE of 12.44%. Recent Q2 2026 earnings beat expectations, driven by 7% revenue growth and a $1 billion buyback announcement, reflecting robust banking and wealth management performance.

Outlook is positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and a recent Citi downgrade. Analyst consensus is mixed with 38.1% buy ratings, suggesting cautious optimism amid a 40% year-to-date run, requiring monitoring of Asia exposure and interest rate trends.